{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T19:45:06Z","timestamp":1779392706948,"version":"3.53.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1 and CTLA-4 have transformed the treatment of malignant melanoma, significantly improving patient survival rates. However, these therapies often result in immune-related adverse events, with cutaneous toxicities being the most prevalent. One such irAE is bullous pemphigoid (BP), which is rare but challenging, and is characterised by autoantibody-mediated blistering at the dermo-epidermal junction. ICI-induced bullous pemphigoid (irBP) affects around 0.6% of patients and presents a therapeutic challenge as it requires the management of both the autoimmune response and the underlying malignancy. Recent research has highlighted the role of Th2 cytokines, particularly interleukin-4 (IL-4) and IL-13, and eosinophils in the pathogenesis of BP and irBP. Dupilumab, a monoclonal antibody that targets the IL-4 receptor alpha subunit, inhibits IL-4 and IL-13 signalling. In this report, we present a case of irBP in a patient with metastatic melanoma who was successfully treated with Dupilumab. Following resolution of the autoimmune skin toxicity, the patient was re-challenged with dual ICI therapy (Nivolumab and Ipilimumab), which remains the recommended first-line treatment for metastatic melanoma. This case highlights the potential of Dupilumab as a steroid-sparing option in the management of irBP, enabling continued oncological treatment.<\/jats:p>","DOI":"10.3389\/fonc.2025.1613552","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:17:15Z","timestamp":1758773835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case Report: Dupilumab therapy for immune checkpoint inhibitor-induced bullous pemphigoid enables dual immunotherapy initiation in progressive malignant melanoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Janine","family":"Gr\u00fcninger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Lehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Meiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rafei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Schauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic therapy for melanoma: ASCO guideline","volume":"38","author":"Seth","year":"2020","journal-title":"JCO"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2019.0119","article-title":"Checkpoint inhibitors","volume":"116","author":"Heinzerling","year":"2019","journal-title":"Dtsch Arztebl Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00201","article-title":"The role of eosinophils in bullous pemphigoid: A developing model of eosinophil pathogenicity in mucocutaneous disease","volume":"5","author":"Amber","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202x.2001.01505.x","article-title":"Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells","volume":"117","author":"Teraki","year":"2001","journal-title":"J Invest Dermatol November"},{"key":"B9","volume-title":"Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid","year":""},{"key":"B10","doi-asserted-by":"publisher","first-page":"2050313X231195462","DOI":"10.1177\/2050313X231195462","article-title":"Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature","volume":"11","author":"Fournier","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3390\/cancers17111845","article-title":"Interleukin-4 and -13 gene expression profiles in immune-related bullous pemphigoid indicate efficacy of IL-4\/IL-13 inhibitors","volume":"17","author":"Arnold","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3872","article-title":"Phase ib\/II trial of ribociclib in combination with binimetinib in patients with NRAS-mutant melanoma","volume":"28","author":"Schuler","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ccell.2025.01.004","article-title":"Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity","volume":"43","author":"Braun","year":"2025","journal-title":"Cancer Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21836","article-title":"Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study","volume":"187","author":"Kawsar","year":"2022","journal-title":"Br J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14097","article-title":"S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid: 2019 update","volume":"18","author":"Schmidt","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.588582","article-title":"Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six german dermatology centers","volume":"11","author":"Sadik","year":"2020","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953546","article-title":"Hemidesmosomal reactivity and treatment recommendations in immune checkpoint inhibitor-induced bullous pemphigoid-A retrospective, monocentric study","volume":"13","author":"Schauer","year":"2022","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19860","article-title":"Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid","volume":"38","author":"Kramer","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bbcan.2015.09.002","article-title":"Signaling pathway and dysregulation of PD1 and its ligands in lymphoid Malignancies","volume":"1865","author":"Xia","year":"2016","journal-title":"Biochim Biophys Acta Januar"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.05.005","article-title":"T follicular regulatory cells in the regulation of B cell responses","volume":"36","author":"Sage","year":"2015","journal-title":"Trends Immunol Juli"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04464.x","article-title":"Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid","volume":"166","author":"G\u00fcnther","year":"2011","journal-title":"Clin Exp Immunol November"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02907.x","article-title":"Characterization of skin cytokines in bullous pemphigoid and pemphigus vulgaris","volume":"140","author":"Rico","year":"1999","journal-title":"Br J Dermatol Juni"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol Dezember"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1007\/s12325-024-02810-3","article-title":"Study design of a phase 2\/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT","volume":"41","author":"Murrell","year":"2024","journal-title":"Adv Ther Juli"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17626","article-title":"Treatment of pembrolizumab-induced bullous pemphigoid with dupilumab: A case report and review of the literature","volume":"64","author":"Barghi","year":"2024","journal-title":"Int J Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01291-2","article-title":"Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy","volume":"23","author":"Grisaru-Tal","year":"2022","journal-title":"Nat Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0138","article-title":"Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy","volume":"9","author":"Moreira","year":"2017","journal-title":"Immunother Januar"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009658","article-title":"Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events","volume":"12","author":"Rubin","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.365","article-title":"LAG3 and its emerging role in cancer immunotherapy","volume":"11","author":"Wang","year":"2021","journal-title":"Clin Transl Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1613552\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:17:16Z","timestamp":1758773836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1613552\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":29,"alternative-id":["10.3389\/fonc.2025.1613552"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1613552","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"article-number":"1613552"}}